

Amendments to the Claims:

This listing of claims will replace all prior versions and listings in this application.

Listing of Claims:

1-83 (Canceled)

84. (New) A crystal of Infliximab.

85. (New) A pharmaceutical composition comprising an antibody crystal wherein said antibody concentration is greater than about 20 mg/ml.

86. (New) A large-batch crystallization method for crystallizing an antibody comprising the following steps:

- a. preparing a series of different micro-batch crystallization solutions, each solution comprising the antibody and a different crystallization buffer;
- b. crystallizing the antibody from each of the micro-batch crystallization solutions;
- c. selecting a micro-batch crystallization solution from the series of solutions that produces antibody crystals of good quality and yield;
- d. preparing a large-batch crystallization solution comprising the antibody and the crystallization buffer that characterized the selected micro-batch crystallization solution; and

e. agitating the large-batch crystallization solution for
between about 3 and about 48 hours at a temperature between about -21°C
and about 61°C, to produce antibody crystals.

87. (New) The large-batch crystallization method according to claim 86,
where the method comprises the additional step of selecting at least one of the
crystallization buffers that characterizes the series of different micro-batch crystallization
solutions by screening various potential buffers for their ability to crystallize the antibody
using a vapor diffusion crystallization method.

88. (New) The large-batch crystallization method according to claim 86
or 87, wherein said method produces crystals within twenty-four hours.

89. (New) The large-batch crystallization method according to claim 86
or 87, wherein said method produces an antibody crystal having substantially similar
properties as the corresponding uncrystallized antibody in at least one of the following
assays: SDS-PAGE (non-reducing conditions), SDS-PAGE (reducing conditions), HPLC
gel filtration, dynamic light scattering, peptide mapping, N-terminal sequencing,
monosaccharide constitution, oligosaccharide profiling, bioassay (direct cytotoxicity) and
bioassay (induced complement dependent toxicity).

90. (New) The large-batch crystallization method according to claim 86
or 87, wherein the antibody is Infliximab.

91. (New) An antibody crystal produced by the large-batch crystallization
method according to any one of claims 86 to 90.